Manufacturers/Genentech, Inc.

Genentech, Inc.

15 drugs in NADAC|0 Generic,15 Brand

View Recalls (4)

Genentech, Inc. lists 15 NDCs in the CMS NADAC file (0 generic, 15 brand), at an average NADAC of $196.52 per unit, with a week-over-week move of -0.1% across products that moved. The firm's full portfolio, pricing trend, and FDA recalls are listed below.

Total Drugs

15

0G / 15B

Avg Price / Unit

$196.5244

$2.43 – $1279.06

Avg 7d Change

-0.07%

Across 6 drugs with changes

7d Activity

69 flat

of 15 total drugs

Portfolio Price Trend

Monthly average NADAC price across all drugs

Frequently Asked Questions

How many drugs does Genentech, Inc. make?

Genentech, Inc. lists 15 NDCs in the CMS NADAC file — 0 generic and 15 brand products.

What is the average price of Genentech, Inc. drugs?

The average NADAC across Genentech, Inc.'s portfolio is $196.5244 per unit, ranging from $2.4329 to $1279.0578.

What types of drugs does Genentech, Inc. make?

Genentech, Inc. makes drugs across 5 FDA pharmacologic classes. The most common by NDC count are Antimetabolite Immunosuppressant (5), Neuraminidase Inhibitor (4), Interleukin-6 Receptor Antagonist (2), Polymerase Acidic Endonuclease Inhibitor (2), Recombinant Human Deoxyribonuclease 1 (1).

Has Genentech, Inc. had any drug recalls?

4 FDA recalls are matched to Genentech, Inc. in the openFDA feed, most recently on May 20, 2024.

How has Genentech, Inc.'s pricing changed recently?

Over the past 7 days, 0 Genentech, Inc. products rose and 6 fell, with a portfolio-wide average change of -0.1%.

Drug Portfolio

15 drugs total, 15 shown

Drug Price 7d Change
ACTEMRA ACTPEN 162 MG/0.9 ML
tocilizumab
$1279.0578
per ML
ACTEMRA 162 MG/0.9 ML SYRINGE
tocilizumab
$1001.1205
per ML
CATHFLO ACTIVASE 2 MG VIAL
Alteplase
$186.3796
per EA
XOFLUZA 80 MG TABLET
BALOXAVIR MARBOXIL
$161.9683
per EA
-0.01%
XOFLUZA 40 MG TABLET
BALOXAVIR MARBOXIL
$161.9466
per EA
-0.02%
PULMOZYME 1 MG/ML AMPUL
dornase alfa
$53.1220
per ML
-0.10%
CELLCEPT 500 MG TABLET
Mycophenolate Mofetil
$17.3742
per EA
-0.08%
CELLCEPT 500 MG TABLET
Mycophenolate Mofetil
$17.3742
per EA
-0.08%
TAMIFLU 75 MG CAPSULE
oseltamivir phosphate
$14.5186
per EA
TAMIFLU 45 MG CAPSULE
oseltamivir phosphate
$13.5402
per EA
TAMIFLU 30 MG CAPSULE
oseltamivir phosphate
$13.3994
per EA
CELLCEPT 250 MG CAPSULE
Mycophenolate Mofetil
$8.6490
per EA
CELLCEPT 250 MG CAPSULE
Mycophenolate Mofetil
$8.6490
per EA
CELLCEPT 200 MG/ML ORAL SUSP
Mycophenolate Mofetil
$8.3330
per ML
-0.15%
TAMIFLU 6 MG/ML SUSPENSION
Oseltamivir Phosphate
$2.4329
per ML

FDA Recalls (4)

Recalls matched by company name. Verify current status with FDA.

D-0509-2024
Terminated
Class II

Cathflo activase (ALTEPLASE), 2mg vials, Rx only, Genentech Inc., South San Francisco, CA 94080, NDC 50242-041-64

Lack of Assurance of Sterility: Deformed stoppers observed during filling operations for Cathflo Activase.

Initiated: 5/20/2024
D-0416-2018
Terminated
Class III

Klonopin (clonazepam) 0.5 mg Tablets,100-count bottle, Rx only. Made in Canada, Distributed by Genentech USA, Inc. A Member of the Roach Group, 1 DNA Way South San Francisco, CA 94080-4990. NDC 0004-0068-01

Labeling: Not Elsewhere Classified: Schedule IV controlled substance indicator of CIV being omitted from the product carton, primary label is correct.

Initiated: 2/5/2018
D-1175-2017
Terminated
Class I

Activase (alteplase), 100 mg (58 million IU), Lyophilized vial, packaged with 1 single-dose 100ml vial of sterile water for Injection USP and one transfer device. Manufactured by: Genentech, Inc. 1 DNA Way, South San Francisco, CA 84080-4990. NDC: 50242-0085-27

Non-Sterility:presence of cracked or chipped glass at the neck of Sterile Water for Injection vials.

Initiated: 9/5/2017
D-097-2013
Terminated
Class III

CellCept (mycophenolate mofetil) capsules, 250 mg, packaged in a) 12 x 120-count bottles per carton, NDC 0004-0259-05; b) 120-count capsules per bottle, NDC 0004-0259-51; Made in Ireland; Distributed by: Genentech USA, Inc., South San Francisco, CA 94080.

Short Fill: some bottles contained less than 120-count per labeled claim.

Initiated: 9/27/2012